3-Amino-1,4-dimethyl-5H-pyrido [4,3-b]indole (Trp-P-1), which is a tryptophan pyrolysate formed during cooking, induces apoptosis in rat splenocytes, thymocytes, and hepatocytes. In this study, we investigated whether Trp-P-1 is transported into these cells and causes apoptosis. Trp-P-1 was immediately incorporated into rat splenocytes, thymocytes, and hepatocytes in a dose-and time-dependent manner. Dopamine and serotonin signiˆcantly competed with the uptake of Trp-P-1 into these cells, and nomifensine and indatraline, which are inhibitors of dopamine-and serotonin-transporters, respectively, markedly suppressed the uptake of Trp-P-1. On the other hand, amino acids including tryptophan did not compete with Trp-P-1. Inhibition of monoamine transporters using nomifensine and indatraline partially suppressed Trp-P-1-induced cell death in these cells. In hepatocytes, the inhibition of transporters prevented Trp-P-1-induced morphological changes and activation of caspase-3. These results demonstrated that Trp-P-1 is incorporated into the cells through monoamine transporters and induces apoptosis.
3-Amino-1,4-dimethyl-5H-pyrido [4,3-b] indole (Trp-P-1), which is well known as a mutagen and carcinogen formed during cooking, 1) induces apoptosis in rat splenocytes and thymocytes, 2) and rat hepatocytes.
3) Trp-P-1-induced apoptosis is accompanied by activation of caspases and apoptotic morphological changes. It is, however, unknown how Trp-P-1 is taken up into these cells, and whether Trp-P-1 intracellularly triggers apoptosis or does it extracellularly.
Although Trp-P-1 is a mutagen and carcinogen, this compound also shows neurotoxic action because of reduction of the catecholamine synthesis-related enzyme activity in clonal rat pheochromocytoma PC12h cells 4) as a model of dopaminergic neurons. Naoi et al. 5) demonstrated that Trp-P-1 was taken up through the dopamine (DA) uptake system in PC12h cells, since the uptake was inhibited by DA and reduced by nomifensine and mazindol, which are speciˆc inhibitors of this system. They also demonstrated that the uptake was inhibited by serotonin (5-HT), which is also a monoamine neurotransmitter similarly to DA, indicating that the uptake may also involve the 5-HT transport system. 5) It is believed that neurotransmitters are released by exocytosis into synaptic clefts and taken back up into nerve endings through speciˆc transporters. 6) In addition, the transport systems of DA and 5-HT exist not only in synapses but also in platelets and lymphocytes. 7, 8) Trp-P-1 was detectable in platelets for at least 9 days after oral administration to rabbits. 9) In this study, we investigated how Trp-P-1 is incorporated into splenocytes, thymocytes, and hepatocytes, and stimulates the apoptotic pathway. Trp-P-1 was rapidly taken up into the splenocytes, thymocytes, and hepatocytes. Experiments using DA and 5-HT as the competitors, or nomifensine and indatraline as the inhibitors of monoamine transporters, showed that the transporters were involved in the uptake of Trp-P-1 into these cells. Furthermore, an inhibition of the uptake suppressed Trp-P-1-induced cell death, caspase activation, and the morphological changes characteristic of apoptosis.
Materials and Methods
Reagents. Trp-P-1 acetate form was purchased from Wako Pure Chemical Industries (Osaka, Japan) and prepared as a stock solution (1000-fold of aˆnal concentration) in DMSO. RPMI 1640 medium for splenocytes and thymocytes and William's medium E for hepatocytes were purchased from Nissui Pharmaceutical (Tokyo, Japan) and Gibco BRL (Grand Island, NY), respectively. Fetal bovine serum (FBS) was from Dainippon Pharmaceutical (Tokyo, Japan). For the inhibitory analyses of Trp-P-1 uptake, the following chemicals were used; L-alanine, Lglutamine, L-cysteine, L-tryptophan, and L-histidine were purchased from Wako Pure Chemical Industries as competitors of the amino acid transport system; dopamine and 5-hydroxytryptamine hydrochloride were obtained from Nacalai Tesque (Kyoto, Japan) and used as the competitors for monoamine transporters; and nomifensine and indatraline as inhibitors of DA or 5-HT transporters were obtained from Sigma Chemical (St. Louis, MO) and Research Biochemicals International (Natick, MA), respectively. All other chemicals were of the highest quality commercially available.
Cell preparation and culture. Splenocytes, thymocytes, and hepatocytes were isolated from male Wistar rats (7 to 8 weeks old, purchased from Japan SLC, Shizuoka, Japan) by the methods described previously. 2, 3) All animal treatments in this study conformed to the``Guidelines for the care and use of experimental animals, in Rokkodai Campus, Kobe University''. Splenocytes and thymocytes were cultured separately at a density of 5×10 6 cells W ml in RPMI 1640 medium containing 5z FBS, 1 mM glutamine, and 1 mg W ml kanamycin. Hepatocytes were cultured at 5×10 5 cells W ml in William's medium E containing 10z FBS, 100 nM insulin, 100 nM dexamethasone, 100 mg W ml kanamycin, and 10 KIU W ml aprotinin. These cells were incubated with experimental reagents in an incubator at 379 C under a 5z CO2 humidiˆed atmosphere.
Quantitative analysis of Trp-P-1. Trp-P-1 incorporated into the cells was measured by high performance liquid chromatography (HPLC) by the method described previously 4) with some modiˆca-tions, after incubation with various concentrations of Trp-P-1 for the incubated time points in Fig. 1 . Splenocytes and thymocytes (2×10 7 ) were collected by a centrifugation at 7,500 g for 30 sec at 49 C, washed twice with PBS, and incubated in 1 ml of PBS containing 1z Triton X-100 for 10 min at 49 C to allow lysis. Hepatocytes (2×10 6 ) were scraped oŠ from the culture dishes with 1 ml PBS containing 1z Triton X-100 after washing with PBS, and then incubated at 49 C for 10 min. Aliquots of 800 ml of lysate were added to 1.5 ml of ethyl acetate, mixed vigorously, and centrifuged at 700 g for 5 min. Aliquot of 1 ml of the ethyl acetate layer was collected and dried, and the residue was dissolved in 500 ml of 50z methanol, andˆltered through a 0.2 mm membraneˆlter. Aliquots of 50 ml ofˆltrate were injected into an HPLC apparatus (Hitachi HPLC 655 connected to a Hitachi variable wavelength UV monitor 638-41). The HPLC conditions were as follows: the column used was a packed reversed-phase column, QC Pack ODS (4.6 mm i.d.×150 mm, Irica Instruments, Kyoto, Japan); mobile phase was 20 mM potassium phosphate: methanol (55: 45; v W v); the ‰ow rate was 1.0 ml W min; the column temperature was 359 C; and Trp-P-1 was measured at a wavelength of 270 nm. Trp-P-1 was measured by comparison of the peak area with that of a standard.
Binding activity of Trp-P-1 to plasma membrane. The plasma membrane fraction was prepared from the fresh liver according to the previous report 10) with slight modiˆcations. In brief, the fresh liver (1 g) was homogenized with 5 ml TE buŠer (10 mM Tris-HCl, pH 7.4, 1 mM EDTA, and 1 mM phenylmethanesulfonyl ‰uoride) containing 0.25 M sucrose, and 1 ml of the homogenate was stored as a liver-homogenate fraction and the remainder was centrifuged at 48,000 g for 20 min. The precipitate was homogenized with 5 ml of the same buŠer, carefully layered on 10 ml TE buŠer containing 1.12 M sucrose, and centrifuged at 100,000 g for 1 h. The intermediate layer was collected and centrifuged with 10 ml TE buŠer at 48,000 g for 45 min. Then, the precipitate was suspended in 500 ml TE buŠer containing 0.25 M sucrose as a plasma membrane fraction. Aliquots (5 mg protein W ml) of the plasma membrane or liver-homogenate fractions were mixed with 30 mM Trp-P-1 and incubated for 5 min at 379 C. The entire volume (500 ml) of the mixture was immediatelyˆltered through a glassˆber lter (pore size, 0.6 mm) in vacuo. Theˆlter was washed twice with 500 ml TE buŠer and transferred into a glass tube with 800 ml TE buŠer. Trp-P-1 was extracted from the residue and theˆltrate with 1.5 ml ethyl acetate, and measured by HPLC as described above.
Measurement of cell viability. Cell viability was measured as total mitochondrial dehydrogenase activity in viable cells using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described previously.
2,3)
Assessment of apoptosis. EŠects of the inhibitors for monoamine transporters on Trp-P-1-induced Fig. 1 . Uptake of Trp-P-1 into Rat Splenocytes, Thymocytes, and Hepatocytes. Splenocytes and thymocytes were incubated with 20 mM Trp-P-1 for the indicated times (A and C, respectively), or with various concentrations of Trp-P-1 for 15 min (B and D, respectively). Hepatocytes were incubated with 30 mM Trp-P-1 for the indicated times (E), or cultured with various concentrations of Trp-P-1 for 10 min (F). Uptake of Trp-P-1 into these cells was measured as described in Materials and Methods, and calculated as nmol per 10 6 cells. The data points represent the means±S.D. of triplicate experiments. Trp-P-1 Incorporated through Monoamine Transporters Induces Apoptosis apoptosis were assessed by morphological changes and caspase activation. The cells were pretreated with the inhibitors for 30 min at the indicated concentration in eachˆgure and treated with Trp-P-1 for 3 h at 20 mM for thymocytes or 30 mM for hepatocytes. The morphological changes were observed using a phasecontrast microscope as described previously.
11)
Cleavage of caspase-3 to the active form was investigated by Western blotting analysis.
12) The caspase-3-like activity in thymocytes was measured using the ‰uorogenic peptide substrate acetyl-Asp-Glu-ValAsp-methylcoumarylamide (Ac-DEVD-MCA) as described previously.
13)

Results
Trp-P-1 is transported into splenocytes, thymocytes, and hepatocytes
Weˆrst investigated whether Trp-P-1 is taken up into splenocytes (Fig. 1 , panels A and B), thymocytes (panels C and D), and hepatocytes (panels E and F) by HPLC. Trp-P-1 was rapidly associated with these cells, and the level of cell-associated Trp-P-1 plateaued within 10 min (Fig. 1 , panels A, C, and E). When splenocytes and thymocytes were treated with Trp-P-1 for 15 min and hepatocytes were treated for 10 min, the uptake was increased in a dose-dependent manner (panels B, D, and F, respectively). The association of Trp-P-1 with the cells seems to be much faster than the transport of substrates such as amino acids. Thus, the binding activity of Trp-P-1 to the plasma membrane was investigated. Liver homogenate or the plasma membrane fraction from the homogenate (5 mg W ml, each protein) was incubated with 30 mM Trp-P-1 for 5 min and separated into theˆltrate containing free Trp-P-1 and the residues containing Trp-P-1 bound to the membranes or particles. Trp-P-1 was not detected in the plasma membrane fraction, although a slight amount (10z) was detected in the residues when the homogenate was used in the incubation mixture (Fig. 2) . The results indicate that Trp-P-1 was immediately transported into cells but not bound to the plasma membranes.
Amino transporters are not involved in the uptake of Trp-P-1 into cells
To know the mechanism of incorporation of Trp-P-1 into these cells, the involvement of amino acid transporters was examined, since Trp-P-1 is derived from tryptophan and 5 kinds of amino acid transporter have been identiˆed in mammalian cells. 14) Hepatocytes were cultured in the medium supplemented with 3 mM amino acid (alanine, glutamine, cysteine, tryptophan, or histidine) simultaneously with 30 mM Trp-P-1 for 30 min. These amino acids did not block but rather slightly increase the uptake of Trp-P-1 into hepatocytes (Fig. 3 ).
Trp-P-1 was transported through monoamine transporters into cells
Next, we examined the involvement of monoamine transporters in the uptake of Trp-P-1. Splenocytes and thymocytes were cultured in the medium containing 20 mM Trp-P-1 with 2 mM DA or 5-HT for 20 min. Both compounds signiˆcantly reduced the uptake into splenocytes and thymocytes (Fig. 4A) . In splenocytes, DA reduced the uptake to 44±2z of Trp-P-1 alone, while 5-HT reduced to 83±2z. In thymocytes, DA and 5-HT decreased the uptake to 60±10 and 60±6z, respectively. Splenocytes, thymocytes, and hepatocytes were cultured in medium containing 20 mM Trp-P-1 with the inhibitors of monoamine transporters, nomifensine for the DA transporter and indatraline for the 5-HT transporter, for 30 min. These inhibitors decreased the uptake of Trp-P-1: nomifensine and indatraline reduced uptake Liver homogenate or plasma membrane fraction from the homogenate was individually incubated with 30 mM Trp-P-1 for 5 min, and separated into the bound (B: solid bar) and free (F: opened bar) form. Trp-P-1 was measured in these fractions as described in Materials and Methods and calculated as the z of content in each fraction. (A) Splenocytes and thymocytes were simultaneously incubated with 20 mM Trp-P-1 and 2 mM DA or 5-HT for 20 min. (B) Splenocytes and thymocytes were incubated in medium containing 2 mM nomifensine or indatraline with 20 mM Trp-P-1 for 20 min. Hepatocytes were incubated in medium containing 3 mM with 30 mM Trp-P-1 for 30 min. Uptake of Trp-P-1 was measured as described in Materials and Methods, and calculated as the z of the control value from cells without inhibitor. The data points represent the means± S.D. of triplicate experiments, and were compared with controls by Student's t-test. Asterisks indicate signiˆcant diŠerences from control ( pº0.05).
to 23±1z and 60±3z, respectively, in splenocytes; to 54±16z and 39±1z, respectively, in thymocytes; and to 47±11z and 36±5z, respectively, in hepatocytes (Fig. 4B) . However, the inhibitory speciˆcity is unlikely to be high because the uptake was inhibited around 50z by a 100-fold excess of inhibitor against Trp-P-1. These results suggested that monoamine transporters are partially involved in the uptake of Trp-P-1 into these cells, and Trp-P-1 may use plural transport systems.
Incorporated Trp-P-1 induces cell death
To determine whether incorporated Trp-P-1 causes cell death, the eŠects of inhibitors for monoamine transporters on Trp-P-1-induced cell death were investigated in hepatocytes, splenocytes, and thymocytes. When hepatocytes were incubated with various concentrations of indatraline or 20 mM nomifensine 30 min before adding 30 mM Trp-P-1 for 4 h ( Fig. 5A) , cell death was signiˆcantly inhibited by indatraline and nomifensine. In splenocytes and thymocytes, pretreatment with 0.5 mM indatraline (Fig. 5B ) also inhibited a reduction of cell viability after treatment with 15 mM Trp-P-1 for 1 h. Nomifensine also showed inhibitory action, i.e. suppression of cell death was 30±13 and 48±21z in splenocytes and thymocytes, respectively, 3 h after treatment with Trp-P-1. These results indicated that incorporated Trp-P-1 exerted cytotoxicity.
Trp-P-1 triggers apoptosis following the transport through monoamine transporters
Since Trp-P-1 causes morphological changes and activation of caspase-3-like proteases, 3, 15) we further studied the eŠects of inhibitors of monoamine transporters on these apoptotic biomarkers in hepatocytes. After pretreatment with 20 mM nomifensine or indatraline for 30 min, hepatocytes were induced to apoptosis by adding 30 mM Trp-P-1 for 3 h. On morphological analyses using phase-contrast microscopy, Trp-P-1-treated hepatocytes showed a round shape with blebbing (Fig. 6B) in comparison with control cells with blocky and tight monolayers (Fig. 6A ). Both nomifensine (Fig. 6C) and indatraline (Fig. 6D) completely prevented Trp-P-1-induced morphological changes. With regard to the activation of caspase, Western blotting analysis of caspase-3 conˆrmed that both inhibitors suppressed cleavage of inactive caspase-3 (32 kDa) into the active form (20 kDa) in hepatocytes (Fig. 7A) . In thymocytes, these inhibitors at 1 mM for a 30-min preincubation also suppressed the activation of caspase-3-like proteases using the ‰uorogenic peptide substrate Ac-DEVD-MCA (Fig. 7B) . Thus, the inhibition of monoamine transporters resulted in suppression of Trp-P-1-induced apoptosis, suggesting that Trp-P-1 triggers apoptosis after transport into cells through monoa- (A) Hepatocytes were pretreated with 20 mM nomifensine or indatraline for 30 min, and then incubated with 30 mM Trp-P-1 or DMSO (vehicle control) for 3 h. Western blotting analysis of caspase-3 was performed using the nuclear protein extracts as described in Materials and Methods. Arrows indicate inactive 32-kDa (p32) and active 20-kDa (p20) forms of caspase-3. (B) Thymocytes were pretreated with 1 mM nomifensine or indatraline for 30 min, and then incubated with 20 mM Trp-P-1 or DMSO (vehicle control) for 3 h. Caspase-3-like activity was measured using the peptide substrate Ac-DEVD-MCA as described in Materials and Methods, and expressed as the z of activity in control cells treated with DMSO alone. The data points represent the means±S.D. of triplicate experiments, and were analyzed by Student's t-test. Asterisks indicate signiˆcant diŠer-ences from the activity in Trp-P-1-treated cells ( pº0.05).
mine transporters.
Discussion
This study was performed to elucidate how Trp-P-1 stimulates the apoptotic pathway, i.e. whether Trp-P-1 intracellularly triggers apoptosis or extracellularly. We demonstrated that Trp-P-1 was taken up into splenocytes, thymocytes, and hepatocytes, at least, in part, through the monoamine transporters, and that the inhibition of the uptake partially suppressed Trp-P-1-induced apoptosis. The incorporated Trp-P-1 into splenocytes and thymocytes was at 0.26±0.02 and 0.16±0.02 nmol W 10 6 cells, respectively, 10 min after treatment with 10 mM Trp-P-1 (Figs. 1B and  1D ). Assuming that a single cell volume of lymphocytes such as splenocytes and thymocytes is about 0.02 mm 3 , the intracellular concentrations of Trp-P-1 were estimated as 16.5 and 8.0 mM in splenocytes and thymocytes, respectively, which were markedly higher than the extracellular concentration. The maximum level of Trp-P-1 incorporated into hepatocytes was signiˆcantly higher than that into splenocytes or thymocytes, although the experimental concentration of Trp-P-1 was diŠerent from that of splenocytes or thymocytes (Fig. 1) . Thus, Trp-P-1 was rapidly incorporated into primary cultured cells.
Naoi et al. 5) reported that the uptake of Trp-P-1 is mediated by the DA uptake system into clonal rat pheochromocytoma PC12h cells. In addition, it has been reported that the DA transport system is distributed not only in neurons but also in lymphocytes 16) and platelets. 17) These results supported our hypothesis that Trp-P-1 would be taken up into splenocytes and thymocytes through the DA transport system. On the other hand, this raises the question of whether Trp-P-1 was transported into cells or bound to the plasma membrane. Lymphocytes are thought to have not only DA transporters but also DA receptors; e.g. LeFur et al. 18) demonstrated the presence of speciˆc binding sites for the D2 receptor antagonist, spiroperidol, on rat and human peripheral lymphocytes. However, the uptake of Trp-P-1 was not only competed by DA (Fig. 4A) but also by the selective DA transporter inhibitor nomifensine (Fig. 4B) . Moreover, Trp-P-1 did not bind to the plasma membrane (Fig. 2) . These results indicated that Trp-P-1 was transported into the cells through DA transporters, but not bound to DA receptors. Naoi et al. 5) also showed that 5-HT inhibited the uptake of Trp-P-1 into PC12h cells, though they admitted that the involvement of the 5-HT transporter in the uptake of Trp-P-1 was still unclear because PC12h cells are a model of dopaminergic, but not serotonergic cells. However, a recent study 7) demonstrated that human lymphocytes have the 5-HT transporter. In this study, we showed that 5-HT (Fig. 4A ) and the selective 5-HT transporter inhibitor indatraline (Fig. 4B) inhibited the uptake of Trp-P-1 into splenocytes, thymocytes, and hepatocytes. It is, therefore, suggested that these cells express not only the DA transporter but also the 5-HT transporter, both of which are involved in the uptake of Trp-P-1.
In splenocytes, DA and 5-HT showed diŠerent inhibitory e‹ciencies at the same concentration, but they caused an equal inhibition in thymocytes (Fig. 4A) . In addition, nomifensine and indatraline showed diŠerent inhibitory fashions in splenocytes, although their ways of inhibition in thymocytes and hepatocytes were almost the same pattern (Fig. 4B ).
These diŠerences may be due to expression levels of monoamine transporters or a‹nity of antidepressants for the transporter. It was reported that the inhibitory eŠects of indatraline on uptake of [ 3 H]-DA into human lymphocytes were stronger than those of nomifensine. 8) Although nomifensine is known as an inhibitor of DA-transporter, it also bind to norepinephrine transporter with high a‹nity. 19) Thus, the uptake of Trp-P-1 may be mediated not only by DA and 5-HT transporters but also by the norepinephrine transporter, suggesting that monoamine transporters play as important roles in the uptake of Trp-P-1.
Our previous studies 2, 12) demonstrated that pretreatment with Ac-DEVD-aldehyde, an inhibitor of caspase-3-like proteases, suppressed the Trp-P-1-induced DNA fragmentation, which is characteristic of apoptosis, in primary cultured rat hepatocytes and splenocytes. Thus, Trp-P-1 executes apoptotic events such as DNA fragmentation through the activation of caspase-3-like proteases. In this study, the inhibition of monoamine transporters suppressed both the activation of caspase-3 ( Fig. 7) and the morphological changes (Fig. 6 ). Caspase-3 plays an important role not only in DNA fragmentation but also in the morphological changes of apoptosis. 20) Therefore, these results suggest that incorporated Trp-P-1 through monoamine transporters induces apoptosis.
Trp-P-1 shows neurotoxicity as an inhibitory eŠect on DA synthesis, particularly tyrosine 3-monooxygenase and aromatic L-amino acid decarboxylase. 4) DA depletion is considered to cause Parkinson's disease. 21) Parkinsonism is elicited by a neurotoxin such as 1-methyl-4-phenylpyridium ion, 22) which induces apoptosis in dopaminergic neurons. 23) Recently, Bas et al. 24) also reported alterations of the immune system in Parkinson's disease, i.e. decrease in numbers of helper T cells and B cells. In addition, the 1-methyl-4-phenylpyridium ion-induced Parkinson's disease mouse model showed immunological changes in splenocytes, i.e. reduced proliferation in response to mitogens and reduction of IgM antibody production. 25) Trp-P-1 induces apoptosis in various kinds of immunocytes such as rat splenocytes, thymocytes, 2) rat mononuclear cells, and human peripheral blood mononuclear cells. 26) Trp-P-1 may be involved in parkinsonism, although there is no direct evidence that Trp-P-1 elicits the disease. Further studies are required to clarify the involvement of Trp-P-1 in Parkinson's disease.
